White Diamond Research says Pulse Biosciences (PLSE)’ Nano-Pulse Stimulation technology “has a long history of commercial failures which contradict the company’s sky-high valuation of $1B+.” In a research report posted on its website, White Diamond argues Pulse’s new application in benign thyroids will be “another dead end.” The company’s “history of failure will likely continue,” the firm contends.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: